Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients

International Journal of Clinical Oncology

Volumn 19, Issue 2, 2014, Pages 288-296

  Thomaidis, Thomas ^a   Weinmann, Arndt ^a   Sprinzl, Martin ^a   Kanzler, Stephan ^b   Raedle, Jochen ^c   Ebert, Matthias ^d   Schimanski, Carl Cristoph ^a,e   Galle, Peter Robert ^a   Hoehler, Thomas ^f   Moehler, Markus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Leopoldina Hospital   (Germany)

^c III Medical Clinic   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Marien Hospital Darmstadt   (Germany)

^f PROSPER HOSPITAL   (Germany)

Author keywords

Anemia; Capecitabine; Cisplatin; Erythropoietin; Gastric cancer; Irinotecan

Indexed keywords

CAPECITABINE; CISPLATIN; HEMOGLOBIN; IRINOTECAN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STOMACH NEOPLASMS;

EID: 84899930746     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0544-7     Document Type: Article

References (39)

1. Hudis CA, Van Belle S, Chang J et al (2004) rHuEPO and treatment outcomes: the clinical experience. Oncologist 9(Suppl 5):55-69 (Pubitemid 39658346)
2. Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11):2865-2874 (Pubitemid 32538196)
3. Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20(10):2486-2494 (Pubitemid 34525734)
4. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392):1255-1260 (Pubitemid 37324251)
5. Glimelius B, Linne T, Hoffman K et al (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16(2):434-440 (Pubitemid 28135584)
6. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94(16):1211-1220 (Pubitemid 34993871)
7. Aapro M, Osterborg A, Gascon P et al (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23(8):1954-1962
8. Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412-3425 (Pubitemid 28481641)
9. Bohlius J, Schmidlin K, Brillant C et al (2009) Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 8(3):CD007303
10. Canon JL, Vansteenkiste J, Bodoky G et al (2006) Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 98(4):273-284 (Pubitemid 43264711)
11. Senecal FM, Yee L, Gabrail N et al (2005) Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 6(5):446-454 (Pubitemid 43078901)
12. Parkin DM, Whelan SL, Ferlay J et al (2002) Cancer Incidence in Five Continents, Vol. VIII. IARC, Lyon
13. Lambert R, Guilloux A, Oshima A et al (2002) Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 97(6):811-818 (Pubitemid 34106337)
14. Cascinu S, Ficarelli R, Safi MA et al (1997) A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 33(10):1699-1702 (Pubitemid 28123496)
15. Kollmannsberger C, Quietzsch D, Haag C et al (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83(4):458-462 (Pubitemid 30487857)
16. Kornek GV, Raderer M, Schull B et al (2002) Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 86(12):1858-1863
17. Moehler M, Kanzler S, Geissler M et al (2010) A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 21:71-77
18. Bauer P, Kohne K (1994) Evaluation of experiments with adaptive interim analyses. Biometrics 50(4):1029-1041
19. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19(11):2875-2882 (Pubitemid 32538197)
20. Wilson J, Yao GL, Raftery J et al (2007) A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11(13):1-202 (iii-iv)
21. Abbrederis K, Bassermann F, Schuhmacher C et al (2006) Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma. Ann Thorac Surg 82(1):293-297
22. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8):459-460
23. Wun T, Law L, Harvey D et al (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98(7):1514-1520 (Pubitemid 37151508)
24. Juneja V, Keegan P, Gootenberg JE et al (2008) Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 14(11):3242-3247
25. Bohlius J, Weingart O, Trelle S et al (2006) Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 3(3):152-164
26. Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996-5010
27. Tetzlaff ED, Correa AM, Baker J et al (2007) The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 109(10):1989-1995 (Pubitemid 46744192)
28. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78(5):285-291 (Pubitemid 29439263)
29. Hernandez E, Ganly P, Charu V et al (2009) Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin 25(9):2109-2120
30. Blohmer JU, Paepke S, Sehouli J et al (2011) Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 29(28):3791-3797
31. Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23(25):5960-5972
32. Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25(9):1027-1032 (Pubitemid 46596751)
33. Overgaard J, Hoff C, San Hansen H et al (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 5(6):7
34. Aapro M, Leonard RC, Barnadas A et al (2008) Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26(4):592-598 (Pubitemid 351264353)
35. Fujisaka Y, Sugiyama T, Saito H et al (2011) Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer 105(9):1267-1272
36. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19(8):1450-1457
37. Kang JH, Lee SI, Lim do H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13):1513-1518
38. Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15):2306-2314
39. Kim JH, Kim HS, Han AR et al (2012) Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncol Lett 4(4):751-754